Core G ? Proteomics and Systems Biology The Proteomics and Systems Biology Core G was created in 2010 in collaboration with the Case Center for Proteomics and Bioinformatics (CPB). The development of the Core was a direct response to increasing CFAR membership demand for proteomic services. The Core provides state-of-the-art proteomic instrumentation; computational resources and software for systems biology; proteomic methods development; consultation and training. Core G includes dedicated staff who are highly experienced in both structural and quantitative proteomics. Core G staff and CFAR faculty actively collaborate in grant proposals and development of novel technologies to advance CFAR members HIV related research. Over the past 5 years the faculty and staff from Core G have successfully partnered with CFAR scientists obtain $6.5 million in awards for HIV research where proteomics was an essential element. The project include the development novel assays, identification of biomarkers for HIV-induced chronic inflammation, and identification of targets for HIV infection and treatment. All these development projects are well aligned with the strategic foci of the CFAR working groups: Immunopathogenesis, Virology & Cure and Co-morbidities and Co-infections. With the recent recruitment of Dr. Rafick Skaly, who will become co-Director, the Core will be be able to dramatically expand the systems biology and bioinformatics tools available to HIV researchers. Dr. Mark Chance, Director, will continue to oversee the proteomics research. The Core plans to merge the sets of prioritary systems biology tools already available at CWRU with additional tools brought by Dr. Skaly and his team. In addition there will be investment in the development of new software to address challenging problems in analysis of ?omic scale data sets. Finally, Core G will work closely with the Virology, Next Generation Sequencing and Imaging Core, now co-Directed by Dr. Mark Cameron to analyze and compare large transcriptomic and proteomic data sets. The extensive data sets used to by Drs. Sekaly and Cameron to identify immune subset signatures and immune correlates of protection /pathogenesis panels will provide an invaluable resource for the CFAR's extensive programs on T-cell activation.
Our specific aims are: ? To provide advanced proteomic technologies to solve unmet needs in HIV research. ? To develop and apply systems biology tools to solve unmet challenges in analysis of `-omic' data. ? To provide consultation and training. In summary, the primary goal of Core G is to make advanced proteomic instrumentation and systems biology tools available to CFAR members for use in HIV research projects. The Core's skilled and highly approachable support staff assist investigators at every stage from experimental design to data analysis. Although Core G will continue to provide a drop-off service for routine analyses, its true strength lies in the active collaborations with CFAR investigators that have resulted in novel assays, identification of new biomarkers, and identified novel targets for combating HIV infection.

Public Health Relevance

Core G ? Proteomics and Systems Biology The HIV/AIDS pandemic is the single largest threat to global public health. This core provides advanced instruments and tools to help HIV researchers with experimental design and data analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-24
Application #
9468327
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773
Wiredja, Danica D; Tabler, Caroline O; Schlatzer, Daniela M et al. (2018) Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology 15:44
Oliveira, Vitor H F; Perazzo, Joseph D; Josephson, Richard A et al. (2018) Association Between the 6-Minute Walk Test Distance and Peak Cardiorespiratory Fitness Among People Living with HIV Varies by Fitness Level. J Assoc Nurses AIDS Care 29:775-781
Paparisto, Ermela; Woods, Matthew W; Coleman, Macon D et al. (2018) Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity. J Virol 92:
Llewellyn, George N; Alvarez-Carbonell, David; Chateau, Morgan et al. (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192-203

Showing the most recent 10 out of 539 publications